The graft-versus-leukaemia effect in haemotopoietic stem cell transplantation using unrelated donors

Bone Marrow Transplantation

Volumn 30, Issue 11, 2002, Pages 761-768

  Remberger, M ^a   Mattsson, J ^a   Hentschke, P ^a   Aschan, J ^a   Barkholt, L ^a   Svennilson, J ^a   Ljungman, P ^a   Ringden O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CHRONIC DISEASE; CHRONICITY; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; UNIVERSITY HOSPITAL; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BLOOD DONORS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 0036902024     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703735     Document Type: Article

References (41)

1. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
2. Carlens S, Ringdén O, Aschan J et al. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. Clin Transplant 1998; 12: 84-92.
3. Ringdén O, Zwaan F, Hermans J, Gratwohl A, for the Leukemia Working Party of the European Group for Bone Marrow Transplantation. European experience of bone marrow transplantation for leukemia. Transplant Proc 1987; 19: 2600.
4. Perreault C, Decary F, Brochu S et al. Minor histocompatibility antigens. Blood 1990; 76: 1269-1280.
5. Ringdén O, Labopin M, Gluckman E et al. for the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
6. Horowitz M, Gale R, Sondel P et al, Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989; 75: 555-562.
7. Goldman J, Gale R, Horowitz M et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Int Med 1988; 108: 806-814.
8. Ringdén O, Horowitz M, Sondel P. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 18: 1094-1101.
9. Weiden P, Flournoy N, Thomas E et al. Antileukemic effect of graft-versus-host disease in human recipients of allogenic marrow grafts. New Engl J Med 1979; 300: 1068-1073.
10. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 198 1; 304: 1529-1533.
11. Ringdén O, Baryd I, Johansson B et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radial Oncol 1983; 22: 423-428.
12. Ringdén O, Ruutu T, Remberger M et al. for the Nordic Group of Bone Marrow Transplantation. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipient with leukemia. Blood 1994; 83: 2723-2730.
13. Ringdén O, Remberger M, Aschan J et al. Long-term follow-up of a randomized trial comparing T-cell-depletion with a combination of methotrexate and cyclosporin in adult leukemic marrow transplant recipients. Transplantation 1994; 58: 887-891.
14. Remberger M, Svahn B-M, Hentschke P et al. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830.
15. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
16. Remberger M, Ringdén O, Blau I et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells with bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
17. Hägglund H, Ringdén O, Öhman S et al. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1998; 24: 831-836.
18. Thomas E, Storb R, Clift R et al. Bone marrow transplantation I and II. New Engl J Med 1975; 292: 832-843, 895-902.
19. Shulman H, Sullivan K, Weiden P et al. Chronic graft-versus-host syndrome in man: a clinicopathological study of 20 long-term Seattle patients. Am J Med 1980; 69: 204-217.
20. Ringdén O, Båryd I, Gahrton G et al. Early treatment and prophylaxis of graft-versus-host disease using prednisolone. Bone Marrow Transplant 1981; 2: 171-177.
21. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 72: 555-561.
22. Socie G, Devergie A, Cosset JM et al. Low-dose (1 Gy) total lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 49: 657-658.
23. Hymes SR, Morison WL, Farmer ER et al. Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. J Am Acad Dermatol 1985; 12: 30-37.
24. Besnier DP, Chabannes D, Mahe B et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study (see comments). Transplantation 1997; 64: 49-54.
25. Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Ant 1992; 39: 225-235.
26. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
27. Cox D. Regression models and life-tables. JR Stat Soc (Series B) 1972; 34: 187-220.
28. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998; 74: 321-329.
29. Kolb H-J, Schattenberg A, Goldman J et al. for the European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow-grafted patients. Blood 1995; 86: 2041-2050.
30. Dazzi F, Szydlo RM, Craddock C et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
31. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
32. Uzunel M, Mattsson J, Jaksch M et al. The significance of graft-versus-host disease and pretransplant minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001; 98: 1982-1984.
33. Gale RP, Horowitz MM, Weiner RS et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-208.
34. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
35. Ringdén O, Labopin M, Gorin NC et al. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia? Br J Haematol 2000; 111: 1130-1137.
36. Ringdén O, Hermans J, Labopin M et al. for the Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leuk Lymphoma 1996; 24: 71-79.
37. Carlens S, Remberger M, Aschan J, Ringdén O. The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. Biol Blood Marrow Transplant 2001; 7: 31-38.
38. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation (see comments). J Clin Oncol 1997; 15: 433-444.
39. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
40. Zetterquist H, Mattsson J, Uzunel M et al. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 2000; 25: 843-851.
41. Mattsson J, Uzunel M, Tammik L et al. Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976-1985.